Subclinical Interstitial Lung Disease in Rheumatoid Arthritis
CHEST · 2026
DOI: 10.1016/j.chest.2025.11.033 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift CHEST, 2026. Verfasst von Andrew L Ormsby und 4 weiteren Autor:innen. Beteiligte Einrichtung: Department of Medicine, University of Colorado, Aurora, CO. Hauptthemen laut MEDLINE: Arthritis, Rheumatoid, Lung Diseases, Interstitial. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 58 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: NHLBI NIH HHS, NIGMS, American Lung Association.
Abstract (Originalsprache)
TOPIC IMPORTANCE: Subclinical interstitial lung disease (ILD) is common in patients with rheumatoid arthritis (RA). Some patients with subclinical rheumatoid arthritis-associated interstitial lung disease (RA-ILD) will progress to clinical ILD, which is associated with increased morbidity and mortality. Recently, the American College of Rheumatology and American College of Chest Physicians (CHEST) have published guidelines addressing screening for ILD in patients with RA; however, much is unknown about risk of progression or optimal treatment strategies after recognition of subclinical RA-ILD. REVIEW FINDINGS: Prospective studies have reported subclinical ILD in around 25% of patients with RA. Demographic risk factors associated with subclinical disease include older age, male sex, and smoking. RA-specific risk factors for subclinical ILD include higher C-reactive protein and erythrocyte sedimentation rate at RA diagnosis, severity of RA disease activity as measured by the Disease Activity Score 28, and rheumatoid factor and anticyclic citrullinated peptide antibody positivity. Biomarkers associated with subclinical disease include the MUC5B promoter variant and serum levels of matrix metalloproteinase 7, pulmonary and activation-regulated chemokine, and surfactant protein D. The optimal treatment approach for subclinical disease is currently unknown. SUMMARY: Future research should focus on defining high-risk populations that will benefit from screening. Furthermore, understanding disease progression in subclinical RA-ILD and the potential for early intervention to impact the development of clinically significant disease will be critical.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Medicine, University of Colorado, Aurora, CO.
- Department of Medicine, Division of Pulmonary, Critical Care, and Sleep Medicine, University of Kansas Medical Center, Kansas City, KS.
- Department of Medicine, Division of Rheumatology, Aurora, CO.
- Department of Medicine, Division of Pulmonary Sciences and Critical Care Medicine, , University of Colorado, Aurora, CO. Electronic address: joyce.lee@cuanschutz.edu.
Förderung
- NHLBI NIH HHS
- NIGMS
- American Lung Association
- National Institutes of Health
- NHLBI
- Pulmonary Fibrosis Foundation
Zitieren
APA
Ormsby, A. L., Matson, S. M., Griffith, M. R., Demoruelle, M. K., & Lee, J. S. (2026). Subclinical Interstitial Lung Disease in Rheumatoid Arthritis. CHEST. https://doi.org/10.1016/j.chest.2025.11.033
Vancouver
Ormsby AL, Matson SM, Griffith MR, Demoruelle MK, Lee JS. Subclinical Interstitial Lung Disease in Rheumatoid Arthritis. CHEST. 2026. doi:10.1016/j.chest.2025.11.033
BibTeX
@article{Ormsby2026,
author = {Ormsby, Andrew L and Matson, Scott M and Griffith, Melissa R and Demoruelle, M Kristen and Lee, Joyce S},
title = {Subclinical Interstitial Lung Disease in Rheumatoid Arthritis},
journal = {CHEST},
year = {2026},
doi = {10.1016/j.chest.2025.11.033}
}
EUVIMED